Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Paltusotine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Paltusotine [inn], F2ibd1gmd3, 2172870-89-0, 3-(4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl)-2-hydroxybenzonitrile, Benzonitrile, 3-(4-(4-amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl)-2-hydroxy-, 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile
    Molecular Formula
    C27H22F2N4O
    Molecular Weight
    456.5  g/mol
    InChI Key
    GHILNKWBALQPDP-UHFFFAOYSA-N
    FDA UNII
    F2IBD1GMD3
    Paltusotine is an orally bioavailable, nonpeptide somatostatin receptor type 2 (SST2; SSTR2) agonist, with potential growth hormone (GH) secretion-inhibiting and antineoplastic activities. Upon oral administration, paltusotine targets, binds to and activates SSTR2, which leads to an inhibition in the secretion of human growth hormone (hGH) in the pituitary gland and results in decreased production of insulin-like growth factor (IGF-1). This may inhibit IGF-1-mediated cell signaling pathways, and lead to apoptosis. SSTR2 is overexpressed by some neuroendocrine tumor cells, and GH is over-produced in the pituitary gland in acromegaly.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile
    2.1.2 InChI
    InChI=1S/C27H22F2N4O/c28-19-10-18(11-20(29)13-19)24-15-32-25-5-4-16(22-3-1-2-17(14-30)27(22)34)12-23(25)26(24)33-8-6-21(31)7-9-33/h1-5,10-13,15,21,34H,6-9,31H2
    2.1.3 InChI Key
    GHILNKWBALQPDP-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CN(CCC1N)C2=C3C=C(C=CC3=NC=C2C4=CC(=CC(=C4)F)F)C5=CC=CC(=C5O)C#N
    2.2 Other Identifiers
    2.2.1 UNII
    F2IBD1GMD3
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Paltusotine [inn]

    2. F2ibd1gmd3

    3. 2172870-89-0

    4. 3-(4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl)-2-hydroxybenzonitrile

    5. Benzonitrile, 3-(4-(4-amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl)-2-hydroxy-

    6. 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile

    7. Unii-f2ibd1gmd3

    8. Schembl19769109

    9. Bdbm405588

    10. Crn-00808

    11. Us10351547, Compound 2-2

    12. Hy-109155

    13. Cs-0116068

    2.4 Create Date
    2018-06-23
    3 Chemical and Physical Properties
    Molecular Weight 456.5 g/mol
    Molecular Formula C27H22F2N4O
    XLogP35.3
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count3
    Exact Mass456.17616766 g/mol
    Monoisotopic Mass456.17616766 g/mol
    Topological Polar Surface Area86.2 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity727
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1